Warning for substitute dispensing of non-bioequivalence drugs

Published: 2002-04-24 06:59:00

Updated: 2002-04-24 06:59:00

In response to a question raised by a civil petitioner, the Health Insurance Review Agency (HIRA) said that the substitute dispensing should be in principle made available among the drugs having identical bioequivalence profiles. Under the HIRA's authoritative interpretation, it is required that ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK